



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

Visit IR website   
Sign-up for Email alerts

**NASDAQ: RVNC**


Last Trade:	30.50
Trade Time:	4:00 PM ET Feb 23, 2018
Change:	-0.20 <span style="color:red">↓</span> (-0.651%)
Day Range	29.40 - 31.00
52-Week Range	18.00 - 37.45
Volume	259,730

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

### Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... [\(more\)](#)

### Stock Performance



### Press Releases [\[ View all \]](#)

- Feb 22, 2018*  
[Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018](#)
- Feb 14, 2018*  
[Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference](#)
- Feb 1, 2018*  
[Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018](#)
- Jan 8, 2018*  
[Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis](#)
- Jan 4, 2018*  
[Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018](#)

### Upcoming Events [\[ View all \]](#)

- Feb 28, 2018 4:30 PM ET*  
[Revance Therapeutics 2017 Fourth Quarter Financial Results](#)

### Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 28, 2017*  
[Annual Report \(10-K\)](#)
- Mar 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)